Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer (AFFIRM)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT00851084
First received: February 24, 2009
Last updated: June 21, 2013
Last verified: May 2013
  Purpose

The primary objective of the study is to estimate the progression-free survival rate at 12 months for the two arms of the study.

Secondary objectives include the evaluation of overall objective response rate to treatment, progression-free survival, overall survival, safety and documentation of potential immunogenicity of aflibercept.

This study was a non-comparative randomized trial and was not powered for a comparison of any of the efficacy endpoints.

Rather, the aim of the trial was to get, for all endpoints, an estimation of the efficacy and safety of aflibercept combined with a modified FOLFOX6 regimen. In such type of non-comparative randomized trial, the control FOLFOLX6 arm was intended to only act as a check on the similarity of the current patients to the historical controls with respect to clinical outcome when given FOLFOX6 treatment.


Condition Intervention Phase
Colorectal Neoplasms
Neoplasm Metastasis
Drug: aflibercept
Drug: oxaliplatin
Drug: 5-FU
Drug: Folinic Acid
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized, Multinational, Study Of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Progression Free Survival (PFS) Rate at 12 Months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    PFS rate at 12 months was defined as the percentage of patients alive without disease progression at 12 months after randomization. The primary efficacy analysis was based on assessment by the Independent Review Committee (IRC). The study was not powered for comparison of PFS rate at 12 months between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.


Secondary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months) ] [ Designated as safety issue: No ]

    PFS was defined as the time from the date of randomization to the date of tumor progression or death from any cause, whichever occurred first. PFS was based on tumor assessment by the Independent Review Committee (IRC). PFS was estimated from Kaplan-Meier Curves.

    The study was not powered for comparison of PFS between the two arms (non-comparative, open-label study).

    Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.


  • Overall Objective Response Rate (ORR) [ Time Frame: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months) ] [ Designated as safety issue: No ]

    Summary of overall objective response rate based on tumor assessment by the Independent Review Committee (IRC) as per Response Evaluation Criteria in Solid Tumours (RECIST) criteria. ORR was defined as the proportion of patients with confirmed Complete Response (CR) or confirmed Partial Response (PR) relative to the total number of patients in the analysis population.

    Per RECIST v 1.0 target lesions evaluation and assessed by tumor imaging: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): >=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

    The study was not powered for comparison of ORR between the two arms (non-comparative, open-label study).


  • Overall Survival (OS) [ Time Frame: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months) ] [ Designated as safety issue: No ]

    Overall survival was defined as the time from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earliest between the last date the patient was known to be alive and the study cutoff date.

    The study was not powered for comparison of OS between the two arms (non-comparative, open-label study).


  • Number of Participants With Treatment-emergent Adverse Events (TEAE) [ Time Frame: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized ] [ Designated as safety issue: Yes ]
    Summary of treatment-emergent adverse events in the safety population. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used in this study to grade the severity of AEs.

  • Immunogenicity of Intravenous (IV) Aflibercept [ Time Frame: Any time post baseline and 90 days after the last infusion of aflibercept, according to baseline status ] [ Designated as safety issue: No ]
    The antidrug antibody (ADA) assay was evaluated for participants receiving aflibercept.


Enrollment: 268
Study Start Date: February 2009
Study Completion Date: January 2012
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: mFOLFOX6 only
modified FOLFOX6 chemotherapy regimen
Drug: oxaliplatin
administration: IV infusion
Drug: 5-FU
administration: IV infusion
Drug: Folinic Acid
administration: IV infusion
Experimental: mFOLFOX6 + aflibercept
modified FOLFOX6 chemotherapy regimen in combination with aflibercept
Drug: aflibercept
administration: IV infusion
Other Names:
  • ZALTRAP™
  • AVE0005
Drug: oxaliplatin
administration: IV infusion
Drug: 5-FU
administration: IV infusion
Drug: Folinic Acid
administration: IV infusion

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven adenocarcinoma of the colon or the rectum
  • Metastatic disease not amenable to potentially curative treatment

Exclusion Criteria:

  • Prior therapy for metastatic cancer of the colon or the rectum
  • Prior treatment with angiogenesis inhibitors

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00851084

  Hide Study Locations
Locations
Australia
Sanofi-Aventis Investigational Site Number 036004
Douglas, Australia, 4814
Sanofi-Aventis Investigational Site Number 036001
Hunter Region Mail Centre, Australia, 2310
Sanofi-Aventis Investigational Site Number 036003
Hunter Region Mail Centre, Australia, 2310
Germany
Sanofi-Aventis Investigational Site Number 276003
Berlin, Germany, 13353
Sanofi-Aventis Investigational Site Number 276007
Dresden, Germany, 01307
Sanofi-Aventis Investigational Site Number 276001
Hannover, Germany, 30625
Sanofi-Aventis Investigational Site Number 276006
Homberg, Germany, 66421
Sanofi-Aventis Investigational Site Number 276004
Mannheim, Germany, 68167
Sanofi-Aventis Investigational Site Number 276002
Münster, Germany, 48149
Sanofi-Aventis Investigational Site Number 276005
Recklinghausen, Germany, 45659
Italy
Sanofi-Aventis Investigational Site Number 380005
Bari, Italy, 70126
Sanofi-Aventis Investigational Site Number 380001
Firenze, Italy, 50141
Sanofi-Aventis Investigational Site Number 380002
Milano, Italy, 20121
Sanofi-Aventis Investigational Site Number 380003
Taormina, Italy, 98039
Sanofi-Aventis Investigational Site Number 380004
Torino, Italy, 10126
Korea, Republic of
Sanofi-Aventis Investigational Site Number 410003
Busan, Korea, Republic of, 614-735
Sanofi-Aventis Investigational Site Number 410004
Cheongju, Korea, Republic of, 361-711
Sanofi-Aventis Investigational Site Number 410005
Daegu, Korea, Republic of, 700-721
Sanofi-Aventis Investigational Site Number 410002
Daejeon, Korea, Republic of
Sanofi-Aventis Investigational Site Number 410007
Goyang-Si, Gyeonggi-Do, Korea, Republic of, 410-769
Sanofi-Aventis Investigational Site Number 410001
Seoul, Korea, Republic of, 152-703
Sanofi-Aventis Investigational Site Number 410006
Seoul, Korea, Republic of, 120-752
Sanofi-Aventis Investigational Site Number 410008
Ulsan, Korea, Republic of, 682-714
Russian Federation
Sanofi-Aventis Investigational Site Number 643002
Pyatigorsk, Russian Federation, 357500
Sanofi-Aventis Investigational Site Number 643005
Saint-Petersburg, Russian Federation, 197758
Sanofi-Aventis Investigational Site Number 643001
Sochi, Russian Federation, 354057
Spain
Sanofi-Aventis Investigational Site Number 724005
Barcelona, Spain, 08036
Sanofi-Aventis Investigational Site Number 724001
Madrid, Spain, 28040
Sanofi-Aventis Investigational Site Number 724004
Madrid, Spain, 28007
Sanofi-Aventis Investigational Site Number 724002
Sabadell, Spain, 08208
Sanofi-Aventis Investigational Site Number 724007
Santiago De Compostela, Spain, 15706
Sanofi-Aventis Investigational Site Number 724003
Valencia, Spain, 46009
United Kingdom
Sanofi-Aventis Investigational Site Number 826004
Leeds, United Kingdom, LS9 7TF
Sanofi-Aventis Investigational Site Number 826001
Leicester, United Kingdom, LE1 5WW
Sanofi-Aventis Investigational Site Number 826002
Manchester, United Kingdom, M20 4BX
Sanofi-Aventis Investigational Site Number 826003
Slough, United Kingdom, SL2 4HL
Sanofi-Aventis Investigational Site Number 826005
Southampton, United Kingdom, SO16 6YD
Sponsors and Collaborators
Sanofi
Investigators
Principal Investigator: John Zalcberg, MD Peter Mc Callum Cancer Centre, Melbourne, Australia
  More Information

No publications provided

Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT00851084     History of Changes
Other Study ID Numbers: EFC10668, EudraCT 2008-004178-41
Study First Received: February 24, 2009
Results First Received: February 19, 2013
Last Updated: June 21, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Sanofi:
Angiogenesis
Colon cancer
Rectal cancer
Oxaliplatin

Additional relevant MeSH terms:
Colorectal Neoplasms
Neoplasm Metastasis
Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Rectal Diseases
Oxaliplatin
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 29, 2014